Atopic Dermatitis News and Research

RSS
Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.
Researchers identify seven genetic risk loci involved in atopic march

Researchers identify seven genetic risk loci involved in atopic march

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

OSU researchers develop new approach to treat eczema

OSU researchers develop new approach to treat eczema

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals’ CEO establishes stock trading plan

Experts explain how nutrition can influence inflammatory processes and help lower chronic diseases risk

Experts explain how nutrition can influence inflammatory processes and help lower chronic diseases risk

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

New PlasmaDerm solution facilitates faster healing of wounds

New PlasmaDerm solution facilitates faster healing of wounds

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

New research points to potential therapeutic target for treating multiple sclerosis

New research points to potential therapeutic target for treating multiple sclerosis

Scientists identify protein that could help tame severe inflammation

Scientists identify protein that could help tame severe inflammation